Drospirenone: a Latin American perspective for oestrogen-free oral contraception

Vieira, Carolina Sales; Celis, Cuauhtemoc; Galán, Guillermo; Hernández, Luis; Díaz, Inmaculada Clotilde Santos; López, Jorge

doi:10.1080/13625187.2020.1837364

Cited by 2 publications

(2 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Выбор конкретного препарата необходимо проводить с учетом индивидуального анамнеза женщины совместно с пациенткой и врачом либо другим специалистом по планированию семьи. Противозачаточный механизм действия комбинированных таблеток принципиально зависит от их прогестинового компонента [9].…”

Section: риски и использование кок у женщин группы высокого рискаunclassified

Combined hormonal contraception: reasons for refusal and use in high-risk women

Кравченко

2022

Medicinskij alfavit

View full text Add to dashboard Cite

Purpose: the article discusses the possibility of using combined hormonal contraception, the reasons for refusal and the use in women of high-risk groups. Methods: a review of data for 5 years was carried out, the factors that led to the refusal to use this type of contraception were analyzed. Information has been collected on the guidelines for action in patients with a high risk of side effects using combined hormonal contraception. Conclusions: women's fear of adverse events, the formation of health problems, are one of the main reasons for refusing to use contraceptives or completely stopping their use. Future research should explore user bias towards hormonal contraception for a better understanding of birth control, better matching the needs and expectations of women and men today.

show abstract

Section: риски и использование кок у женщин группы высокого рискаunclassified

Combined hormonal contraception: reasons for refusal and use in high-risk women

Кравченко

2022

Medicinskij alfavit

View full text Add to dashboard Cite

show abstract

“…Because of this, it is non‐androgenic, has anti‐mineralocorticoid characteristics, and inhibits the renin angiotensin aldosterone system's estrogen‐stimulated activity. 2 …”

Section: Introductionmentioning

confidence: 99%

Bioequivalence study of low dose drospirenone/ethinyl estradiol 3 mg/0.03 mg film tablets under fasting conditions in Turkish healthy female subjects

Inal,

Sezer,

Uluözlü

et al. 2024

Pharmacology Res & Perspec

View full text Add to dashboard Cite

This bioequivalence research aims to evaluate the relative bioavailability and pharmacokinetic characteristics of ethinyl estradiol and drospirenone in the test preparation in comparison to the reference preparation during fasting conditions. A liquid chromatography method with tandem mass spectrometry was used to determine the concentrations of drospirenone and ethinyl estradiol in plasma. The pharmacokinetic parameters that were analyzed were the maximum plasma concentration (Cmax), time to achieve Cmax (tmax), elimination half life, and area under the concentration time curve of plasma (AUC0‐t, AUC0‐∞ for ethinyl estradiol, and AUC0‐72h for drospirenone). Both the AUC and Cmax parameters were determined to be between 80.00% and 125.00% (90% confidence intervals), which is the acceptable range. Based on the study findings, it was concluded that the test formulation, which includes 3 mg of drospirenone and 0.03 mg of ethinyl estradiol, demonstrated bioequivalence when compared to the reference formulation.

show abstract

Drospirenone: a Latin American perspective for oestrogen-free oral contraception

Cited by 2 publications

References 40 publications

Combined hormonal contraception: reasons for refusal and use in high-risk women

Combined hormonal contraception: reasons for refusal and use in high-risk women

Bioequivalence study of low dose drospirenone/ethinyl estradiol 3 mg/0.03 mg film tablets under fasting conditions in Turkish healthy female subjects

Contact Info

Product

Resources

About